However, PD DDI, which is much more frequent in patients with cancer, should be considered in addition to PK.12 Modern targeted cancer therapies such as ipilimumab and various tyrosine kinase inhibitors are associated with increased risk of bleeding and interaction with all anticoagulants regardless of interaction with cytochrome P450 or P-glycoprotein. This evidence concerns the gene ABCB1 and cancer.